Annual Report 2025-26 and 31st AGM Notice

Profit growth above 25%EBITDA margin expansionResults View source PDF Explain this filing

AMANTA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.8%Reaction day

₹195.83

prior close

₹203.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.3%+4.5% vs market

Pharmaceuticals peers, median of 176sector-0.2%+5.0% vs sector

On the reaction day the stock moved 4.5 pts more than Nifty Microcap 250 and 5.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+0.5

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.8+0.3+4.5-0.2+5.0

Next day

-0.5-0.2-0.3-0.4-0.0

-2.5+0.4-2.9-0.0-2.4

-4.4+0.2-4.6+0.0-4.4

-6.3+0.5-6.8+0.5-6.9

-3.6+0.8-4.4+0.5-4.1

-4.0-0.8-3.2+0.8-4.8

15d

-1.0-2.1+1.1+0.4-1.5

-3.4+0.2-3.6+2.1-5.5

-16.0-9.2-6.8-6.4-9.6

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 176Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Amanta Healthcare filed its FY26 Annual Report ahead of the 31st AGM on September 16, 2026 via video conferencing. Revenue rose to 288 cr from 275 cr, EBITDA held at 63 cr with a 22.2% margin, and PAT jumped over 42% to 15 cr. Debt-to-equity improved sharply from 3.43x to 1.06x since FY23. The company listed on BSE and NSE in September 2025.

Likely market impact

Strong profit growth and major deleveraging reflect improving fundamentals; modest revenue growth and expansion capex remain key watchpoints for investors.